{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:34:49Z","timestamp":1786653289616,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0019-509x.175301","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T06:37:37Z","timestamp":1454481457000},"page":"582","source":"Crossref","is-referenced-by-count":3,"title":["The outcome effect of double-hormonal therapy in premenopausal breast cancer patients with high nodal-status: Result of a prospective randomized trial"],"prefix":"10.4103","volume":"51","author":[{"given":"B","family":"Zengel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Akpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Postaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Corumlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kebapci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Aykas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.175301-1","first-page":"2651","volume-title":"Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer.National cancer \u0131nstitute of Canada clinical trials group","author":"Levine","year":"1998","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-2","first-page":"886","volume-title":"Selection of adjuvant chemotherapy for treatment of node-positive breast cancer","author":"Trudeau","year":"2005","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0019-509X.175301-3","first-page":"976","volume-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-4","first-page":"3686","volume-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-5","first-page":"275","volume-title":"Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient","author":"Jonat","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-6","first-page":"1110","volume-title":"Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial","author":"Ganz","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-7","first-page":"1431","volume-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:First report of \u0131ntergroup trial C9741\/cancer and leukemia group B trial 9741","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-8","first-page":"2302","volume-title":"Adjuvant docetaxel for node-positive breast cancer","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.175301-9","first-page":"1869","volume-title":"Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?","author":"Aebi","year":"2000","journal-title":"Lancet"},{"key":"key-10.4103\/0019-509X.175301-10","first-page":"1711","volume-title":"Survival analyses from the ZEBRA study.goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer","author":"Kaufmann","year":"2003","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.175301-11","first-page":"5973","volume-title":"Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188)","author":"Davidson","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.175301-12","first-page":"252","volume-title":"International breast cancer study group.Clinical trial update: International breast cancer study group","author":"Price","year":"2005","journal-title":"Breast Cancer Res"},{"key":"key-10.4103\/0019-509X.175301-13","first-page":"137","volume-title":"Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer.10-year update of international breast cancer study group trial 11-93?","author":"Th\u00fcrlimann","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0019-509X.175301-14","first-page":"1231","volume-title":"Premenopausal endocrine-responsive early breast cancer: Who receives chemotherapy?","author":"Regan","year":"2008","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.175301-15","first-page":"2087","volume-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials","author":"Clarke","year":"2005","journal-title":"Lancet"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:34:49Z","timestamp":1786649689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0019-509X.175301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"alternative-id":["175301"],"URL":"https:\/\/doi.org\/10.4103\/0019-509x.175301","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}